MedImmune is focused on developing and marketing products that address medical needs in areas such as infectious disease, immunology and cancer. The company's capabilities span the entire spectrum of pharmaceutical development, including discovery, research, clinical development, data analysis, regulatory affairs, quality control, manufacturing, and sales and marketing.

	As MedImmune's flagship product, Synagis® helps to prevent respiratory syncytial virus (RSV), the most common cause of lower respiratory tract infections in infants. To date, more than 600,000 children have benefited from the protection Synagis provides. To learn more about Synagis, including Important Safety & Prescribing Information, click here.
	Ethyol® helps to improve the lives of many cancer patients by reducing the impact of certain side effects of both radiotherapy and chemotherapies. To learn more about Ethyol, including Important Safety & Prescribing Information, click here.
	Now approved for children as young as two years old, the nasal spray flu vaccine FluMist® (Influenza Virus Vaccine Live, Intranasal) helps to protect eligible children and adults two to 49 years of age against influenza. FluMist is different from the flu shot in that it uses live, attenuated – or weakened – viruses within the vaccine to help stimulate an immune response that is designed to closely resemble the body’s natural response to an influenza infection. To learn more about FluMist, including Important Safety & Prescribing Information, click here.